INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
- TRADE NAME: Vraylar (Forest)
- INDICATIONS: Schizophrenia; manic or mixed episodes associated with bipolar I disorder
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 2–4 days
- FDA APPROVAL DATE: 09/17/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inducers - PREGNANCY: Neonatal risk in third trimester exposure
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/21/2024
